Long-term survival following autologous and allogeneic stem cell transplantation for blastic plasmacytoid dendritic cell neoplasm

We sought to clarify the role of high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (auto-HSCT) and allogeneic hematopoietic stem cell transplantation (allo-HSCT) to treat blastic plasmacytoid dendritic cell neoplasm (BPDCN). We retrospectively identified 25 BPDCN...

Full description

Saved in:
Bibliographic Details
Published inBlood Vol. 125; no. 23; pp. 3559 - 3562
Main Authors Aoki, Tomohiro, Suzuki, Ritsuro, Kuwatsuka, Yachiyo, Kako, Shinichi, Fujimoto, Katsuya, Taguchi, Jun, Kondo, Tadakazu, Ohata, Kinya, Ito, Toshiro, Kamoda, Yoshimasa, Fukuda, Takahiro, Ichinohe, Tatsuo, Takeuchi, Kengo, Izutsu, Koji, Suzumiya, Junji
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 04.06.2015
Subjects
Adolescent
Adult
Aged
Autografts
Dendritic Cells - pathology
Disease-Free Survival
Female
Follow-Up Studies
Hematopoietic Stem Cell Transplantation
Humans
Male
Middle Aged
Plasmacytoma - mortality
Plasmacytoma - pathology
Plasmacytoma - therapy
Retrospective Studies
Survival Rate
Online AccessGet full text

Cover

More Information
Summary:We sought to clarify the role of high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (auto-HSCT) and allogeneic hematopoietic stem cell transplantation (allo-HSCT) to treat blastic plasmacytoid dendritic cell neoplasm (BPDCN). We retrospectively identified 25 BPDCN patients (allo-HSCT, n = 14; auto-HSCT, n = 11) from registry data of the Japan Society for Hematopoietic Cell Transplantation and analyzed clinicopathologic data and clinical outcomes after transplantation. The median age at HSCT was 58 years (range, 17-67 years). All 11 patients who underwent auto-HSCT were in the first complete remission (CR1). With a median follow-up of 53.5 months, the overall survival rates at 4 years for patients who underwent auto-HSCT and allo-HSCT were 82% and 53% (P = .11), respectively, and progression-free survival rates were 73% and 48% (P = .14), respectively. Auto-HSCT for BPDCN in CR1 appears to provide promising results and deserves further evaluation in the setting of prospective trials. •Auto-HSCT in CR1 provides long-term remission in BPDCN patients.•RIC allo-HSCT and MAC allo-HSCT results are comparable.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ISSN:0006-4971
1528-0020
DOI:10.1182/blood-2015-01-621268